

CERTIFICATE OF MAILING

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED  
WITH THE UNITED STATES POSTAL SERVICE WITH SUFFICIENT POSTAGE  
AS FIRST-CLASS MAIL IN AN ENVELOPE ADDRESSED TO:

COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450,

ON 3/31/04

M. J. F. F.  
NAME  
3/31/04  
DATE

Attorney Docket No. B45198D1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Wettendorf

Serial No.: 10/734,857

Group Art Unit No.: Unknown

Filed: 12 December 2003

Examiner: Unknown

For: NOVEL COMPOSITION

Commissioner for Patents  
P.O. Box 1450  
Alexandria VA, 22313-1450

Filing of an Information Disclosure Statement under 37 C.F.R. §1.97(c) and  
Certification under 37 C.F.R. §1.97(e)(1) or (e)(2)

Information Disclosure Statement. The attached list of citations on PTO Form 1449 is being submitted under the provisions of 37 CFR §1.56 and §1.97 in order to comply with the duty of disclosure. Their inclusion herein should not, however, be construed as an admission that any particular cited reference is effective prior art or that it discloses or renders obvious any aspect of the claimed invention. Copies of each are enclosed, except for those references already part of the filewrapper. This statement is being filed with the required Certification and without any fee, in accordance with the provisions of 37 C.F.R. §1.97(c)(1) and (2), i.e., before a Final Action under 37 CFR §1.113 or a Notice of Allowance under 37 CFR §1.311.

Serial No.: 10/734,857  
Group Art Unit No.: Unknown

Statement of Certification. The undersigned hereby certifies either:

(a) that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement, or


(b) that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and to the knowledge of the undersigned after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of this Statement.

Respectfully submitted,



William R. Majarian  
Attorney for Applicants  
Registration No. 41,173

GLAXOSMITHKLINE  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, PA 19406-0939  
Phone (610) 270-5968  
Facsimile (610) 270-5090  
N:\Will\APPS\B-cases\B45198\DI-ids.doc

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET NO. <b>B45198D1</b>	SERIAL NO. <b>10/734,857</b>
 <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use several sheets if necessary)</i>		APPLICANT <b>Wettendorff</b>	
		FILING DATE <b>12/12/03</b>	GROUP <b>Unknown</b>

**U.S. PATENT DOCUMENTS**

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

**FOREIGN PATENT DOCUMENTS**

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent Pages, Etc.)

	Roden et al., "Assessment of the Serological Relatedness of Genital Human Papillomaviruses by Hemagglutination Inhibition", Journal of Virology, vol. 70, no. 5, May 1996, pgs 3298-3301
	Wheeler, "Preventive Vaccines for Cervical Cancer", Salud Publica De Mexico, vol. 39, no. 4, July 1997, pgs 283-287
	Schiller et al., "Papillomavirus-Like Particles and HPV Vaccine Development", Seminars in Cancer biology, Saunders Scientific Publications, vol. 7, no. 6, pgs 373-382
	Suzich et al., "Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas", Proceedings of the National Academy of Sciences of USA, National Academy of Science, vol. 92, 1995, pgs 11553-11557
	Lowe et al., "Human Papillomavirus Type 11 (HPV-11) Neutralizing Antibodies in the Serum and Genital Mucosal Secretions of African Green Monkeys Immunized with HPV-11 Virus-Like Particles Expressed in Yeast", Journal of Infectious Diseases", vol. 176, no. 5, 1997 pgs 1141-1145

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.